Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1936

1.

The power of proteasome inhibition in multiple myeloma.

Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG.

Expert Rev Proteomics. 2018 Nov 14:1-20. doi: 10.1080/14789450.2018.1543595. [Epub ahead of print]

PMID:
30427223
2.

Ixazomib for the treatment of multiple myeloma.

Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S.

Expert Opin Pharmacother. 2018 Nov 13:1-20. doi: 10.1080/14656566.2018.1528229. [Epub ahead of print]

PMID:
30422008
3.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

4.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ.

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov.

5.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
6.

Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis.

Lancaster KE, Hoffman IF, Hanscom B, Ha TV, Dumchev K, Susami H, Rose S, Go VF, Reifeis SA, Mollan KR, Hudgens MG, Piwowar-Manning EM, Richardson P, Dvoriak S, Djoerban Z, Kiriazova T, Zeziulin O, Djauzi S, Ahn CV, Latkin C, Metzger D, Burns DN, Sugarman J, Strathdee SA, Eshleman SH, Clarke W, Donnell D, Emel L, Sunner LE, McKinstry L, Sista N, Hamilton EL, Lucas JP, Duong BD, Van Vuong N, Sarasvita R, Miller WC; HPTN 074 Study Team.

J Int AIDS Soc. 2018 Oct;21(10):e25195. doi: 10.1002/jia2.25195.

7.

Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis.

Stuver R, Petersen A, Guerrero-Garcia TA, Matulonis U, Richardson P, Singh P.

Case Rep Hematol. 2018 Sep 24;2018:3029650. doi: 10.1155/2018/3029650. eCollection 2018.

8.

Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era.

Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ.

Clin Genitourin Cancer. 2018 Sep 19. pii: S1558-7673(18)30413-0. doi: 10.1016/j.clgc.2018.09.009. [Epub ahead of print]

PMID:
30309761
9.

Rapid quantification of the adulteration of fresh coconut water by dilution and sugars using Raman spectroscopy and chemometrics.

Richardson PIC, Muhamadali H, Ellis DI, Goodacre R.

Food Chem. 2019 Jan 30;272:157-164. doi: 10.1016/j.foodchem.2018.08.038. Epub 2018 Aug 9.

PMID:
30309526
10.

Quantification of hyperpolarisation efficiency in SABRE and SABRE-Relay enhanced NMR spectroscopy.

Richardson PM, John RO, Parrott AJ, Rayner PJ, Iali W, Nordon A, Halse ME, Duckett SB.

Phys Chem Chem Phys. 2018 Nov 7;20(41):26362-26371. doi: 10.1039/c8cp05473h. Epub 2018 Oct 10.

PMID:
30303501
11.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Richardson PG, Grupp SA, Pagliuca A, Krishnan A, Ho VT, Corbacioglu S.

Int J Hematol Oncol. 2017 Nov;6(3):75-93. doi: 10.2217/ijh-2017-0015. Epub 2017 Aug 11. Review.

12.

Sleep moderates the association between routines and emotion regulation for toddlers in poverty.

Bocknek EL, Richardson PA, van den Heuvel MI, Qipo T, Brophy-Herb HE.

J Fam Psychol. 2018 Oct;32(7):966-974. doi: 10.1037/fam0000433. Epub 2018 Oct 4.

PMID:
30284864
13.

A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynolds CH, Shain K, Zackon I, Stampleman L, Henrick P, Rivotto BJ, Hornburg K, Dumke H, Chuma S, Savell A, Handisides D, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2018 Oct 2. pii: clincanres.1325.2018. doi: 10.1158/1078-0432.CCR-18-1325. [Epub ahead of print]

PMID:
30279233
14.

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Downey-Kopyscinski S, Daily EW, Gautier M, Bhatt A, Florea BI, Mitsiades CS, Richardson PG, Driessen C, Overkleeft HS, Kisselev AF.

Blood Adv. 2018 Oct 9;2(19):2443-2451. doi: 10.1182/bloodadvances.2018016360.

15.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Sep 24. pii: blood-2018-06-858613. doi: 10.1182/blood-2018-06-858613. [Epub ahead of print]

PMID:
30249784
16.

Can acoustic radiation force imaging of the liver and spleen predict the presence of gastroesophageal varices?

Wiles R, Patanwala I, Hankinson B, Healey P, Farrell C, Griffin C, Bonnett L, Richardson P.

Clin Radiol. 2018 Sep 21. pii: S0009-9260(18)30509-9. doi: 10.1016/j.crad.2018.07.199. [Epub ahead of print]

PMID:
30245070
17.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.

PMID:
30218008
18.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.

Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.

PMID:
30204239
19.

Quantitative In Situ Monitoring of Parahydrogen Fraction Using Raman Spectroscopy.

Parrott AJ, Dallin P, Andrews J, Richardson PM, Semenova O, Halse ME, Duckett SB, Nordon A.

Appl Spectrosc. 2018 Sep 11:3702818798644. doi: 10.1177/0003702818798644. [Epub ahead of print]

PMID:
30203662
20.

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.

Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, Rose SM, Latkin CA, Metzger DS, Lancaster KE, Go VF, Dvoriak S, Mollan KR, Reifeis SA, Piwowar-Manning EM, Richardson P, Hudgens MG, Hamilton EL, Sugarman J, Eshleman SH, Susami H, Chu VA, Djauzi S, Kiriazova T, Bui DD, Strathdee SA, Burns DN.

Lancet. 2018 Sep 1;392(10149):747-759. doi: 10.1016/S0140-6736(18)31487-9.

PMID:
30191830
21.

Treatment Patterns in Veterans with Laryngeal and Oropharyngeal Cancer and Impact on Survival.

Richardson PA, Kansara S, Chen GG, Sabichi A, Sikora AG, Parke RB, Donovan DT, Chiao E, Sandulache VC.

Laryngoscope Investig Otolaryngol. 2018 Aug 9;3(4):275-282. doi: 10.1002/lio2.170. eCollection 2018 Aug.

22.

Short-Term Impact of Bariatric Surgery on Best-Corrected Distance Visual Acuity and Diabetic Retinopathy Progression.

Richardson P, Hulpus A, Idris I.

Obes Surg. 2018 Nov;28(11):3711-3713. doi: 10.1007/s11695-018-3445-z.

PMID:
30173284
23.

Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis.

Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, Thursz MR, Allison M; STOPAH Trial Management Group.

J Hepatol. 2018 Nov;69(5):1200-1201. doi: 10.1016/j.jhep.2018.06.019. Epub 2018 Aug 24. No abstract available.

PMID:
30150133
24.

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG.

Clin Adv Hematol Oncol. 2018 Aug;16(8):564-574. Review.

PMID:
30148829
25.

Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM, Chu J, El-Serag HB.

Gastroenterology. 2018 Aug 23. pii: S0016-5085(18)34889-3. doi: 10.1053/j.gastro.2018.08.024. [Epub ahead of print]

PMID:
30144434
26.

[Ln16] complexes (Ln = GdIII, DyIII): molecular analogues of natural minerals such as hydrotalcite.

Richardson P, Hsu TJ, Kuo CJ, Holmberg RJ, Gabidullin B, Rouzières M, Clérac R, Murugesu M, Lin PH.

Dalton Trans. 2018 Oct 7;47(37):12847-12851. doi: 10.1039/c8dt02609b. Epub 2018 Aug 24.

PMID:
30141810
27.

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC.

Leukemia. 2018 Aug 22. doi: 10.1038/s41375-018-0242-6. [Epub ahead of print]

PMID:
30135465
28.

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS.

JAMA Oncol. 2018 Aug 16:e183267. doi: 10.1001/jamaoncol.2018.3267. [Epub ahead of print]

PMID:
30128502
29.

Conjunctival ultraviolet autofluorescence area, but not intensity, is associated with myopia.

Kearney S, O'Donoghue L, Pourshahidi LK, Richardson P, Laird E, Healy M, Saunders KJ.

Clin Exp Optom. 2018 Aug 16. doi: 10.1111/cxo.12825. [Epub ahead of print]

PMID:
30114725
30.

Variation in postacute care utilization after complex surgery.

Balentine CJ, Mason MC, Richardson PJ, Kougias P, Bakaeen F, Naik AD, Berger DH, Anaya DA.

J Surg Res. 2018 Oct;230:61-70. doi: 10.1016/j.jss.2018.04.052. Epub 2018 May 25.

PMID:
30100041
31.

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2018 Aug 3. pii: S1083-8791(18)30428-2. doi: 10.1016/j.bbmt.2018.07.039. [Epub ahead of print]

PMID:
30081073
32.

Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study.

Wang Z, White DL, Hoogeveen R, Chen L, Whitsel EA, Richardson PA, Virani SS, Garcia JM, El-Serag HB, Jiao L.

J Clin Med. 2018 Aug 2;7(8). pii: E197. doi: 10.3390/jcm7080197.

33.

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.

Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R.

Neurology. 2018 Aug 28;91(9):403-413. doi: 10.1212/WNL.0000000000006083. Epub 2018 Jul 27. Review.

PMID:
30054438
34.

Association between intensity of statin therapy and mortality in persons with chronic kidney disease.

Walther CP, Richardson PA, Virani SS, Winkelmayer WC, Navaneethan SD.

Nephrol Dial Transplant. 2018 Jul 20. doi: 10.1093/ndt/gfy237. [Epub ahead of print]

PMID:
30053252
35.

Nivolumab Treatment for Cancers in the HIV-infected Population.

Chang E, Sabichi AL, Kramer JR, Hartman C, Royse KE, White DL, Patel NR, Richardson P, Yellapragada SV, Garcia JM, Chiao EY.

J Immunother. 2018 Oct;41(8):379-383. doi: 10.1097/CJI.0000000000000240.

PMID:
30020193
36.

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT.

Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.

Southampton (UK): NIHR Journals Library; 2018 Jun.

37.

How I treat the young patient with multiple myeloma.

Gandolfi S, Prada CP, Richardson PG.

Blood. 2018 Sep 13;132(11):1114-1124. doi: 10.1182/blood-2017-05-693606. Epub 2018 Jul 2. Review.

PMID:
29967130
38.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574. [Epub ahead of print]

PMID:
29965787
39.

Kinetically guided radical-based synthesis of C(sp3)-C(sp3) linkages on DNA.

Wang J, Lundberg H, Asai S, Martín-Acosta P, Chen JS, Brown S, Farrell W, Dushin RG, O'Donnell CJ, Ratnayake AS, Richardson P, Liu Z, Qin T, Blackmond DG, Baran PS.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6404-E6410. doi: 10.1073/pnas.1806900115. Epub 2018 Jun 26.

PMID:
29946037
40.

The use of defibrotide in blood and marrow transplantation.

Richardson PG, Carreras E, Iacobelli M, Nejadnik B.

Blood Adv. 2018 Jun 26;2(12):1495-1509. doi: 10.1182/bloodadvances.2017008375. Review. Erratum in: Blood Adv. 2018 Aug 14;2(15):1853.

41.

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.

Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.

42.

Maintenance and continuous therapy for multiple myeloma.

Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P.

Expert Rev Anticancer Ther. 2018 Aug;18(8):751-764. doi: 10.1080/14737140.2018.1490181. Epub 2018 Jul 3.

PMID:
29932776
43.

SABRE hyperpolarization enables high-sensitivity 1H and 13C benchtop NMR spectroscopy.

Richardson PM, Parrott AJ, Semenova O, Nordon A, Duckett SB, Halse ME.

Analyst. 2018 Jul 9;143(14):3442-3450. doi: 10.1039/c8an00596f.

44.

ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established.

Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, Thursz MR, Allison M; STOPAH Trial Management Group.

Am J Gastroenterol. 2018 Jun 11. doi: 10.1038/s41395-018-0076-x. [Epub ahead of print] No abstract available.

PMID:
29887598
45.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA.

Pediatr Blood Cancer. 2018 Oct;65(10):e27269. doi: 10.1002/pbc.27269. Epub 2018 Jun 6.

PMID:
29873895
46.

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG.

Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29.

47.

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.

Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, Lonial S.

Br J Haematol. 2018 Jun;181(5):628-636. doi: 10.1111/bjh.15248. Epub 2018 May 17.

PMID:
29774521
48.

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, Lehmann L, Shore T, Ho VT, Bunin N, Iacobelli M, Liang W, Hume R, Tappe W, Soiffer R, Richardson P.

Br J Haematol. 2018 Jun;181(6):816-827. doi: 10.1111/bjh.15267. Epub 2018 May 16.

49.

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.

de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P.

Hepatol Commun. 2018 Mar 23;2(5):492-503. doi: 10.1002/hep4.1170. eCollection 2018 May.

50.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Mar 29. doi: 10.1038/s41375-018-0116-y. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center